Scholarlink

<p>Smoking cessation is the central causal intervention in the treatment of chronic obstructive pulmonary disease (COPD). While inhaled pharmacotherapies can alleviate symptoms and reduce exacerbations, smoking cessation is the only intervention that can halt disease progression. Tobacco smoke induces chronic inflammation of the airways and lung parenchyma through numerous toxic and carcinogenic substances. Despite a&#xa0;confirmed diagnosis, a&#xa0;substantial proportion of patients with COPD continue to smoke. This highlights the high addictive potential of nicotine and the need for structured, low-threshold support. Smoking behavior should be consistently and repeatedly assessed and documented in all patients with COPD, including the use of alternative nicotine products. Patients who smoke should be counselled using an opt-out approach through a&#xa0;brief intervention (for example according to the ABC model). The most effective approach to tobacco cessation combines counselling with pharmacotherapy. Counselling interventions, with greater intensity generally associated with greater effectiveness, can include referral to telephone counselling, referral to a&#xa0;smoking cessation course, prescription of a&#xa0;digital health application (in Germany) or behavioral therapy. Pharmacotherapy primarily includes nicotine replacement therapy and the pharmacological options bupropion, varenicline and cytisine. Since 2025 Germany has for the first time allowed pharmacotherapy for tobacco cessation to be prescribed within certain limits at the expense of statutory health insurance funds. So-called alternative nicotine products, such as e‑cigarettes and heated tobacco products, should not be used in patients with COPD who smoke tobacco, neither as an alternative nor as a&#xa0;cessation aid. Increasing evidence describes their harmful potential, dual use is common and behavioral patterns are maintained that can hinder complete abstinence from smoking and nicotine.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tabakrauchen und COPD: Rauchstopp ist Basis der Therapie

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月7日

查看全文
  • Lukasz Antoniewicz,
  • Matthias Raspe

摘要

Smoking cessation is the central causal intervention in the treatment of chronic obstructive pulmonary disease (COPD). While inhaled pharmacotherapies can alleviate symptoms and reduce exacerbations, smoking cessation is the only intervention that can halt disease progression. Tobacco smoke induces chronic inflammation of the airways and lung parenchyma through numerous toxic and carcinogenic substances. Despite a confirmed diagnosis, a substantial proportion of patients with COPD continue to smoke. This highlights the high addictive potential of nicotine and the need for structured, low-threshold support. Smoking behavior should be consistently and repeatedly assessed and documented in all patients with COPD, including the use of alternative nicotine products. Patients who smoke should be counselled using an opt-out approach through a brief intervention (for example according to the ABC model). The most effective approach to tobacco cessation combines counselling with pharmacotherapy. Counselling interventions, with greater intensity generally associated with greater effectiveness, can include referral to telephone counselling, referral to a smoking cessation course, prescription of a digital health application (in Germany) or behavioral therapy. Pharmacotherapy primarily includes nicotine replacement therapy and the pharmacological options bupropion, varenicline and cytisine. Since 2025 Germany has for the first time allowed pharmacotherapy for tobacco cessation to be prescribed within certain limits at the expense of statutory health insurance funds. So-called alternative nicotine products, such as e‑cigarettes and heated tobacco products, should not be used in patients with COPD who smoke tobacco, neither as an alternative nor as a cessation aid. Increasing evidence describes their harmful potential, dual use is common and behavioral patterns are maintained that can hinder complete abstinence from smoking and nicotine.